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Pharmacodynamics of Imipenem in Combination with -Lactamase
Inhibitor MK7655 in a Murine Thigh Model
Eleftheria Mavridou,a,b Ria J. B. Melchers,a Anita C. H. A. M. van Mil,b E. Mangin,c Mary R. Motyl,c Johan W. Moutona,b,d
Radboud University Nijmegen Medical Center, Nijmegen, The Netherlandsa; Canisius Wilhelmina Hospital, Nijmegen, The Netherlandsb; Erasmus University Medical
Centre, Rotterdam, The Netherlandsd; Merck & Co., Inc., West Point, Pennsylvania, USAc
MK7655 is a newly developed beta-lactamase inhibitor of class A and class C carbapenemases. Pharmacokinetics (PK) of imi-
penem-cilastatin (IMP/C) andMK7655 were determined for intraperitoneal doses of 4 mg/kg to 128 mg/kg of body weight. MIC
and pharmacodynamics (PD) studies of MK7655 were performed against several beta-lactamase producing Pseudomonas
aeruginosa and Klebsiella pneumoniae strains to determine its effect in vitro and in vivo. Neutropenic mice were infected in each
thigh 2 h before treatment with an inoculum of approximately 5 106 CFU. They were treated with IMP/C alone (every 2 hours
[q2h], various doses) or in combination withMK7655 in either a dose fractionation study or q2h for 24 h and sacrificed for CFU
determinations. IMP/MK7655 decreasedMICs regarding IMPMIC. The PK profiles of IMP/C andMK7655 were linear over the
dosing range studied and comparable with volumes of distribution (V) of 0.434 and 0.544 liter/kg and half-lives (t1/2) of 0.24 and
0.25 h, respectively. Protein binding of MK7655 was 20%. A sigmoidal maximum effect (Emax) model was fit to the PK/PD index
responses. The effect of the inhibitor was not related to the maximum concentration of drug in serum (Cmax)/MIC, andmodel
fits for T>MIC and area under the concentration-time curve (AUC)/MIC were comparable (R
2 of 0.7 and 0.75), but there appeared
to be no significant relationship of effect with dose frequency. Escalating doses of MK7655 and IMP/C showed that the AUC of
MK7655 required for a static effect was dependent on the dose of IMP/C and theMIC of the strain, with a mean area under the
concentration-time curve for the free, unbound fraction of the drug (fAUC) of 26.0 mg · h/liter. MK7655 shows significant activ-
ity in vivo and results in efficacy of IMP/C in otherwise resistant strains. The exposure-response relationships found can serve as
a basis for establishing dosing regimens in humans.
Antimicrobial resistance is an emerging problem worldwide(1), and until this decade, the development of new classes of
antibiotics had been an important weapon for combating this.
Carbapenems are one of these classes, represented by drugs such
as imipenem and meropenem. As broad-spectrum antibiotics,
these drugs have been the mainstay of treatment against multiply
resistant Gram-negative bacilli and infections caused by them.
These infections are difficult to treat and include those due to
Pseudomonas aeruginosa and multidrug-resistant Klebsiella spp.
(2). However, strains have recently emerged that carry carbapen-
emases (enzymes that destroy carbapenems), rendering them re-
sistant to all carbapenems (3). One approach to overcoming this
mode of resistance is by inhibition of these enzymes. This ap-
proach has successfully been applied in the past for other beta-
lactamases, for instance clavulanic acid (4, 5) and tazobactam (6,
7). The new compound MK7655 is a beta-lactamase inhibitor
(BLI) that has been shown to inhibit several types of beta-lacta-
mases, including carbapenemases (8). In vitro studies have shown
that the MICs for resistant strains were drastically reduced in the
presence ofMK7655 and thereby became susceptible to imipenem
(8, 9). The next step in determining the feasibility ofMK7655 is to
determine its effect in vivo and the doses and concentrations that
are required to overcome resistance. Pharmacokinetics (PK) and
pharmacodynamics (PD) studies to determine exposure-effect re-
lationships of antimicrobials have become a mainstay in optimiz-
ing dosing regimens and determining breakpoints (10–12).
PK/PD relationships of combinations pose a specific challenge. In
this study, we determined the pharmacodynamics of MK7655
during imipenem-cilastatin (IMP/C) treatment of experimental
infections with IMP/C-resistant bacteria. Our strategy was to first
determine the PK/PD relationship of IMP/C. This allowed choos-
ing doses of IMP/C to result in amoderate increase in the dCFUof
two selectedP. aeruginosa andKlebsiella pneumoniae strains (i.e., a
change of 1- to 2-log10 growth). Doses of MK7655 were then var-
ied in a dose fractionation study to determine the pharmacody-
namic index (PI) of the inhibitor. In subsequent experiments, the
initial observations were further validated by documenting the
efficacy of MK7655 against a number of other IMP/C-resistant
strains.
MATERIALS AND METHODS
Setting. In vivo experiments were carried out in the Central Animal Facil-
ity (Centraal Dierenlab) at Radboud University Nijmegen Medical Cen-
tre. The animal studies were conducted in accordance with the recom-
mendations of the European Community Directive 86/609/EEC, 24
November 1986. The study was approved by the animal welfare commit-
tee of Radboud University (approval no. RU-DEC 2009-060).
Drugs. For the in vitro susceptibility testing, imipenem (IMP) and
MK7655 were provided by Merck. The drugs were reconstituted in phos-
phate buffer (0.01 mol/liter, pH 7.2) to a stock solution of 5,120 mg/liter.
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Working solutions were prepared inMueller-Hinton broth (MH) (Difco,
Brunschwig Chemie, Amsterdam, The Netherlands). For the in vivo stud-
ies, MK7655 was supplied by Merck. Imipenem-cilastatin was obtained
commercially as powder for injection. The drugs were reconstituted in
0.9%NaCl to a final concentration of 14.08 mg/ml, except for the highest
concentration of IMP/C (128 mg/ml), where the final concentration was
28.16mg/ml. Subsequently, solutions were combined and/or diluted with
0.9% NaCl to their final concentrations. The solutions were stored at
80°C until use and were used within 5 days.
Strains. P. aeruginosa ATCC 27853 and K. pneumoniae ATCC 43816
were used for infections in the PK experiments. For the PK/PD studies, 5
different Pseudomonas and 2 Klebsiella strains with various MICs and
beta-lactamase expressions were selected from strains provided byMerck.
The characteristics of these strains are shown in Table 1.
In vitro susceptibility testing. Susceptibility testing for imipenemwas
performedby a brothmicrodilution assay following the ISO20776-1:2006
international standard protocol against rapidly growing aerobic bacteria
(13). MICs for each agent in combination were determined by checker-
board titrations in MH broth. Doubling dilutions of imipenem and
MK7655were freshly prepared inMHbroth to give a concentration 4-fold
greater than the desired concentration. We dispensed 25 l of imipenem
(range, 512 to 0.25 mg/liter) in the columns of a microdilution tray. We
also dispensed 25l MK7655 (range, 64 to 0.5 mg/liter) in the rows of the
same tray. The trays were stored at 80°C until use. We added 50 l
bacterial suspension (1 106 CFU/ml) to the thawed trays and incubated
them overnight. Each tray contained a growth control and a negative
control. The recorded MIC was the lowest concentration of imipenem/
MK7655 that completely inhibited visible growth. All titrations were done
at least in duplicate. MK7655 dilutions ranging from 0.125 mg/liter to 16
mg/liter were tested to determine whether they exhibited any antimicro-
bial activity.
Animals. Outbred female CD1 mice (weighing 20 to 22 g at arrival)
were used in all the experiments and were obtained from Charles River
(SulzFeld, Germany). The mice were rendered neutropenic by intraperi-
toneal injection of cyclophosphamide at 150 mg/kg of body weight 4 days
before the experiment (day4) and 100 mg/kg at day1. Animals were
housed two per cage and received water and food ad libitum.
Infection. On the day of the experiment, animals were infected with
an inoculum of 0.1 ml in both thighs, each with a different strain. The
inoculumwas prepared by standard procedures. In brief, for each strain, a
batch of 50 ml was prepared in MH broth (Difco, Brunschwig Chemie,
Amsterdam, The Netherlands) by inoculation and growth to a final con-
centration of 108 to 109 bacteria/ml. Each batch was divided equally into
50 microtubes and stored at 80°C. Growth curves were generated on sep-
arate days to determine the reproducibility and colony count of the inoc-
ulum after thawing. On the day of infection, a 0.5-ml aliquot was thawed
and added to 4.5 ml prewarmed MH broth. After incubation for 1 h, this
was diluted to a final inoculum of approximately 5 106 bacteria. Anti-
microbial treatment (t 0 h) was started 2 h after infection.
Pharmacokinetics. Single-dose plasma pharmacokinetic studies were
performed for IMP/C andMK7655 in thigh-infectedmice. Themice were
injected intraperitoneally with 0.1 ml (0.2 ml for the highest dose) of a
solution containing IMP/C and MK7655 in combination 2 h after infec-
tion. The following doseswere applied: 8/4, 16/8, 32/16, 64/32, and 128/64
mg/kg, respectively. Blood samples were taken before injection (t 0 h)
and at 0.167, 0.33, 0.5, 0.75, 1, 1.5, 2, 3, 4, and 6 h after injection. Before
collection by retro-orbital bleeding, the mice were anesthetized by using
isoflurane. Samples were immediately put on ice and subsequently cen-
trifuged. The supernatant, approximately 0.25 ml, was added to a 0.5-ml
morpholineethanesulfonic acid (MES) buffer (pH 6.0). The exact amount
of plasma was determined by weighing the samples. Samples were stored
at 80°C, and concentrations were determined by high-pressure liquid
chromatography (HPLC) at Merck (USA). The analytical methods for
TABLE 2 MICs of strains used for imipenem at different concentrations of MK7655a
Strain
MIC of IMPb (mg/liter) combined with MK7655c concn (mg/liter) of:
0 0.125 0.25 0.5 1 2 4 8 16
P. aeruginosa
ATCC 27853 1 1/2 1 0.5 0.25/0.5 0.25 0.25 0.25 0.25
24354 32 32 32 16/32 8/32 8/16 2/4 2 1
24227 4 4 2/4 2 1 0.5 0.25/0.5 0.25 0.25
24226 8 8 4/8 2/4 0.5/2 0.5/1 0.5 0.5 0.25/0.5
24228 8 4/8 4 4 2 1 0.5 0.5 0.5
K. pneumoniae
ATCC 43816 0.25 0.125 0.125/0.25 0.125 0.125 0.125/0.25 0.125 0.125 0.125
6755 4 0.5 0.25 0.25 0.125 0.125 0.125 0.06/0.125 0.0625
6339 16 4 4 2 0.5/1 0.25 0.125/0.25 0.125 0.0625
a Current EUCAST breakpoints: susceptible,2 mg/liter (K. pneumoniae) and 4 mg/liter (P. aeruginosa); resistant,8 mg/liter. Current CLSI breakpoints: susceptible,1 mg/liter
(K. pneumoniae) or2 (P. aeruginosa); intermediate, 2 mg/liter (K. pneumoniae) or 4 mg/liter (P. aeruginosa); resistant,4 mg/liter (K. pneumoniae) or8 mg/liter (P.
aeruginosa).
b IMP, imipenem.
c MICs were obtained in duplicate; two values indicate incongruent results.
TABLE 1 Characteristics of the strains used
Species Strain Resistance summarya
P. aeruginosa
ATCC 27853
24354 OprD, AmpCcon, class A,
class B
24227 OprD, AmpCind, class A,
class B
24226 OprD, AmpCcon, class A,
class B
24228 OprD, AmpCind, class A,
class B





a ind, inducible; con, constitutive; red, reduced expression; AmpC and class C,
cloxacillin susceptible; class A, clavulanic acid susceptible; class B, EDTA susceptible;
KPC-2*, KPC type inferred from ribotyping identity to NYC epidemic clone.
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determination ofMK7655 and IMP/C are based on the extraction of drug
from plasma via protein precipitation. MK7655, IMP/C, and internal
standards are separated using hydrophilic interaction chromatography
(HILIC) and detected via tandem mass spectrometry in the turbo-ion
spray (TIS) mode. The lower limit of quantification (LLOQ) for each
analyte was 0.25 g/ml, with a linear calibration range of 0.25 to 100
g/ml. For each time point, 2 mice were used.
Pharmacokinetic analysis.Concentrations were plotted against time.
One- and two-compartment models with and without an absorption
phase were fitted to the data using WinNonlin (version 2.1; Pharsight
Corp., St. Louis, MO) and GraphPad Prism version 5.0 (GraphPad, Inc.,
San Diego, CA). Using the parameter estimates obtained, simulations of
concentration-time profiles of IMP/C and MK7655 in mice were carried
out usingMicLab 2.33 (Medimatics, Maastricht, The Netherlands). From
these, the fTMIC was determined for a range of MICs and dosing regi-
mens of IMP/C andMK7655. For IMP/C andMK7655, a protein binding
of 20% was taken (Merck, data on file [14]).
Pharmacodynamic studies. Animals were treated with IMP/C or
sham treated with a control (saline) every 2 h for 24 h with or without
MK7655 at various doses and frequencies (see below). At 0 h, 2 mice were
humanely sacrificed to determine the number of CFU just before treat-
ment. All the other animals were sacrificed at 24 h unless the welfare of the
animals necessitated earlier termination, in accordance with animal wel-
fare regulations. Excised thighs were transferred to a precooled 10-ml
plastic tube (Transport Tube, Omnilabo, The Netherlands) containing 2
ml PBS and were homogenized using an Ultra-Turax homogenizer (IKA
Labortechnik, Germany). A 10-fold dilution series was prepared, and 3
10 l was plated per dilution. The following day, the CFU were counted.
The drug effect was determined as the difference between the 10-log CFU
values at 24 h and 0 h (mean value of 2 mice) expressed as d log CFU. For
the dose fractionation study of MK7655, IMP/C was given at a fixed dose
every 2 h, while MK7655 was then varied in such a way that an optimal
variation in exposure would be obtained for the three major PK/PD indi-
ces maximum concentration of free, unbound drug in serum (fCmax)/
MIC,%fTMIC, and area under the concentration-time curve for the free,
unbound fraction of drug (fAUC)/MIC. All dosing regimens were per-
formed with at least two animals. For the dose fractionation study of
MK7655, two dosing regimens of IMP/C were chosen, based on the effi-
cacy of IMP/C inmonotherapy experiments, corresponding to doses pro-
ducing a static effect and a 2-log10 increase in the number of CFU with
IMP/C alone. For further quantification of the effects ofMK7655 for other
strains, a dosing regimen of 8 mg/kg IMP/C every 2 h was used, corre-
sponding to%fTMIC values of 46.1% at anMIC of 1mg/liter, 34.2% at 2
mg/liter, and 22.4% at 4 mg/liter.
Pharmacodynamic analysis. d log CFUwas plotted against total daily
doses, area under the concentration-time curve (AUC), fTC, andCmax of
MK7655 and the fTMIC of IMP/C alone. The Hill model with variable
slope was fitted to the data using GraphPad Prism 5.0 (San Diego, CA).
The static PIs were determined from the model fit.
RESULTS
In vitro studies. Table 2 provides the results of the checkerboard
experiments. At low concentrations, there was no effect of the
inhibitor, as indicated by a 0-fold difference in MIC compared to
the control. Increasing the concentration of the inhibitor resulted
in an increasing effect until a certain plateau was reached. The
MK7655 concentration at which the plateau was reached and the
plateau itself varied for each strain. MK7655 alone showed no
antibacterial activity.
Pharmacokinetics of imipenem and MK7655. A one-com-
partment model best fit the data. IMP/C andMK7655 showed no
dose-dependent pharmacokinetics. The PK profiles of IMP/C and
MK7655 were linear over the dosing range studied. The IMP/C
andMK7655V values were 0.434 and 0.544 liter/kg, and the elim-
ination half-lives were 0.24 and 0.25 h, respectively.
Pharmacodynamics studies. The PD of IMP/C alone was de-
termined for each of the seven strains studied. Figure 1 shows
examples of the dose-response relationship of IMP/C given every
2 h (q2h) for two strains, whereas Table 3 provides the pharma-
codynamic characteristics of IMP/C for each strain. Subsequently,
a dose fractionation study was performed for MK7655. Strains P.
aeruginosa 24228 andK. pneumoniae 6755were chosen to evaluate
exposure-response relationships. Doses of MK7655 (from 4 to 64
mg/kg) and the frequencies of administration (1 to 12 times daily)
were varied. The IMP/C dosing regimens used were determined
from the exposure-response relationship of IMP/C alone (see
above) and set at the two doses that would result in an approxi-
mately 2-log10 increase inCFU and a static effect, respectively. The
efficacy of MK7655 would then be indicated as a decrease in CFU
relative to the controls andwould be relatively sensitive to changes
FIG 1 Dose-response relationship for IMP/C given q2h in thigh-infected mice. (Left) P. aeruginosa 24226; (Right) K. pneumoniae 6755.
TABLE 3 Pharmacodynamic properties of 5 P. aeruginosa and 2 K.










24226 426.6 8 53.32 36.40
24227 25.1 4 6.28 0.00
24228 208.9 8 26.12 23.60
24354 549.5 32 17.17 15.60
24349 45.7 16 2.86 0.00
6755 182.0 4 45.49 33.00
6339 1479.1 16 92.44 45.20
a TDD, total daily dose.
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in concentration of the inhibitor. Figure 2a and b show the rela-
tionship between exposure and effect for various PIs for strainsK.
pneumoniae 6755 and P. aeruginosa 24228. The effect was clearly
dependent on the presence ofMK7655 in a dose-dependent man-
ner. There did not appear to be any relationship betweenMK7655
peak concentration (Cmax) and efficacy. There appears to be a
stronger relationship between AUC and dose compared to that
between TMIC and dose, indicating that the total daily dose and
AUC are the primary drivers of outcome. In addition, a separate
analysis of the dose fractionation study fitting themaximumeffect
(Emax) model for each dose frequency showed no significant rela-
tionship between 50% effective concentration (EC50) and dose
frequency, indicating that the effect was primarily dependent on
total daily dose and therefore AUC. The effect of MK7655 was
studied further in five other strains, primarily to further validate
and quantify the relationship betweenMK7655 concentration and
effect. Because the dose fractionation study had indicated that the
total daily dose (orAUC)was the PK/PD index that best correlated
with outcome,MK7655 doses were administered at the same time
as those of IMP/C. Figure 3 shows the exposure-response relation-
ships for 5 strains treated with 8 mg/kg IMP/C every 2 h
(22.4%fTC at 4 mg/liter; 0%fTC at 16 mg/liter). This IMP/C
dosewas chosen because it resulted in%fTMIC values relevant for
clinically achievable concentrations. For each strain, a clear expo-
sure effect of MK7655 was observed.
Interaction between imipenem andMK7655. For two strains,
K. pneumoniae 6339 and P. aeruginosa 24226, the effect of
MK7655 was studied for four different dosing regimens of IMP/C
(1, 2, 4, and 8 mg/kg every 2 h). The main purpose of this exper-
iment was to determine whether the effect of MK7655 was depen-
FIG 2 Dose-response relationship of MK7655 observed in dose fractionation studies with IMP/C administered q2h at fixed doses. (a) K. pneumoniae 6755; (b)
P. aeruginosa 24228. tdd, total daily dose.
FIG 3 Dose-response relationship of MK7655 in combination with IMP/C 8
mg/kg q2h for 5 strains.
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dent on the IMP/C dose and/or if there was a certain MK7655
AUC threshold for effect. Figure 4 shows the exposure-response
relationships for the two strains, indicating that at the lowest dose
of IMP/C administered, MK7655 effects were still apparent but
marginal.
Quantitation of the effect of the inhibitor. Table 4 summa-
rizes the exposures and effects of IMP/C and MK7655 for all the
experiments. Since the dose fractionation experiments indicated
that fAUCwas the parameter best correlatedwith effect, this index
is shown in the table. The static MK7655 fAUC values of the indi-
vidual experiments ranged from approximately 6 mg · h/liter (P.
aeruginosa 24227 and K. pneumoniae 6339) up to 45.2 mg · h/liter
(P. aeruginosa 24354); P. aeruginosa 24354 exhibited the highest
MIC. The mean fAUC required was 26.0 mg · h/liter. The table
also shows the MIC of each strain in the presence of 8 mg/liter
MK7655, as well as the %fTMIC of IMP/C corresponding to
the MIC.
DISCUSSION
In this study, the effect of MK7655 during treatment with imi-
penem was determined using doses otherwise too low to demon-
strate any efficacy during single-drug therapy. MK7655 in combi-
nation with IMP/C showed significant activity in vitro and in vivo,
as it resulted in efficacy against imipenem-resistant strains. The
PK/PD relationship of MK7655 described indicates that the AUC
is the parameter that best correlates with efficacy. In the dose
fractionation experiment, the best fit was obtained using the total
daily dose or AUC. The results also show that MK7655 efficacy is
clearly not related to peak concentration (Cmax). These observa-
tions suggest that the timing ofMK7655 administration relative to
that of imipenem is not critical and supports the potential for
coadministration of MK7655 and IMP/C in a single formulation.
The total amount of MK7655 that is needed to render a given
strain susceptible to imipenem in vivo is a matter of debate. In the
FIG4 Dose-response relationship ofMK7655 in combinationwith IMP/C q2h at four different dose levels forK. pneumoniae 6339 (left) and P. aeruginosa 24226
(right).

















6339 1 12 16 0 0.25
2 24 16 0 0.25
4 48 16 0 0.25
8 96 16 0 11.8 6.3 0.25
6755 8 96 4 22.4 75.9 40.3 0.125
15.9 190.8 4 34.1 39.8 21.2 0.125
24266 1 12 8 0 0.5
2 24 8 0 61.7 32.8 0.5
4 48 8 0 79.4 42.2 0.5
8 96 8 10.5 23.4 12.5 0.5
24354 8 96 32 0 85.1 45.2 2
24227 8 96 4 22.4 12 6.4 0.25
24228 15.9 190.8 8 22.3 51.3 27.2 0.5
Mean 48.9 26.0
SD 27.1 14.4
a TDD, total daily dose of imipenem.
b The static fAUC indicates the exposure of MK7655 to result in a static effect with the imipenem regimes.
c MIC/4, imipenem MIC in the presence of 4 mg/liter MK7655.
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experiments described here, the MK7655 AUC required to result
in a static effect of imipenem ranged from 6 to 45 mg · h/liter
(mean, 26 mg · h/liter). This value may serve as a basis for deter-
mining the doses of MK7655 once the human PK profile of
MK7655 has been determined in phase 1 clinical trials (15), taking
into consideration the protein binding of MK7655 (20% in mice
[14]). While 7 strains have been studied to date and therefore a
reasonable characterization of the variation that may be present
between strains has been quantified, the effect of MK7655 is not
only strain dependent but also dependent on the imipenem dos-
ing regimen. In fact, the doses of imipenemused in this studywere
relatively low, and the results for MK7655 are therefore conserva-
tive. Theoretically, if all enzyme (beta-lactamase) activity is neu-
tralized by aBLI, that strainwould appear susceptible, aswild-type
K. pneumoniae and P. aeruginosa are each imipenem susceptible.
Using a dosing regimen of 8mg/liter and a clinical breakpoint of 2
mg/liter (the EUCAST S breakpoint), the %fTMIC is 34.2%, and
this value correlates with the static effects observed in animal
models described by others. For each strain, an MK7655 regimen
that resulted in a static effect at clinically achievable concentra-
tions was found. Considering that the number of approvals for
new antibacterial agents are still dropping and the existing -lac-
tamase inhibitors are poorly active against class C and D enzymes
and not active against class B enzymes, MK7655 is a promising
-lactamase inhibiter and will restore the activity of imipenem
against carbapenemases; thus, it warrants clinical evaluation.
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